Industries · Dermatology & Cosmetics
From ex vivo skin explants to microbiome swabs, OMICS4 runs the molecular evidence behind your efficacy claims and mechanism-of-action studies, in-house and through our dermo-cosmetic partner network.
Overview
From ex vivo skin explants to microbiome swabs, OMICS4 supports dermo-cosmetic R&D teams with the molecular evidence needed to substantiate efficacy claims and understand mechanism of action. Specialist dermo-cosmetic expertise is available through our partners DIVA Expertise and PKDERM, alongside our in-house transcriptomics and metagenomics platforms.
OMICS4 capabilities
Transcriptomic efficacy signal from treated vs untreated explants.
Microbiome shifts tracked from low-biomass skin swabs.
Statistically defensible molecular evidence for claims and regulatory review.
Candidate biomarkers and mechanism hypotheses for new actives, delivered by GenXMap's Computational Biology & AI layer on top of our wet-lab data.
How OMICS4 adapts
No two programs run the same workflow. Here is how OMICS4 fits into what you already have in place.
Claims substantiation needs data that stands up to regulatory and marketing review (EU Cosmetic Regulation, FTC).
Reports are structured with the statistical rigor and traceability your claims and regulatory teams need to sign off.
Explant and swab material is limited, fragile, and often low-biomass.
Wet lab protocols are adapted for low-input, low-biomass samples to preserve signal quality.
Product development runs on tight, iterative testing cycles: formulation v1, v2, v3.
Fast-turn, standardized reporting lets you compare formulation iterations directly, cycle over cycle.
Findings need to be understood by both scientific and non-scientific stakeholders (marketing, regulatory affairs).
Deliverables include both the full technical report and a plain-language summary for cross-functional teams.
Have a project in this space?